Molecular Trial Schedule 2024-205 - Version: 1.1. Index: Administration 794. Printed: 01-Dec-2023 12:21

Leucocyte Immunophenotyping

Sheffield Teaching Hospitals NHS Foundation Trust

Molecular Haemato-Oncology Trial Schedule 2024 – 2025

Accredited Programmes	Trial issue	APR 24	MAY 24	JUN 24	JUL 24	AUG 24	SEP 24	OCT 24	NOV 24	DEC 24	JAN 25	FEB 25	MAR 25
BCR::ABL1 and AML Translocation Identification	3	х				х				х			
BCR::ABL1 Kinase Domain Variant (Mutation) Status	3			х				х				х	
BCR::ABL1 Major Quantification	3		х				х				х		
BCR::ABL1 Minor Quantification	3		х				х				х		
BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia	3	х			х					х			
FLT3 Mutation Status	3				х				х				х
IG/TCR Clonality Status	3	х				х				х			
KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease	3		x		2		х				х		
Myeloproliferative Neoplasms Diagnostic Testing ¹	4			x			х			х			х
NPM1 Mutation Status	3				х				х				х
Paediatric Acute Leukaemia Translocations	3			x				x				х	
Post-Stem Cell Transplant Chimerism Monitoring	5		х		х			х		х		х	_

Non-accredited Programmes	Trial Issue	APR 24	MAY 24	JUN 24	JUL 24	AUG 24	SEP 24	OCT 24	NOV 24	DEC 24	JAN 25	FEB 25	MAR 25
Lymphoid Gene Panels	2						X ²						Х 3
Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia	2			x					x				
Measurable Residual Disease for Acute Myeloid Leukaemia by Molecular Methods	2					x							х
Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods	2			х					x				
Myeloid Gene Panels	2					X ²						X ³	

^{1.} The JAK2 p.V617F mutation status and MPN DT programmes have now been merged and includes testing of JAK2 p.V617F, JAK2 exon 12, CALR and MPL. Please note, only the JAK2 p.V617F aspect of testing is currently accredited. We are avoiding towards accreditation for the other markers and dictudes educational variant interpretation; 3. Technical focus